摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

mirtazapine hydrate

中文名称
——
中文别名
——
英文名称
mirtazapine hydrate
英文别名
mirtazapine water;5-methyl-2,5,19-triazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(15),8,10,12,16,18-hexaene;hydrate
mirtazapine hydrate化学式
CAS
——
化学式
C17H19N3*H2O
mdl
——
分子量
283.373
InChiKey
MHSHMTBXVDLHCQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.65
  • 重原子数:
    21
  • 可旋转键数:
    0
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.35
  • 拓扑面积:
    20.4
  • 氢给体数:
    1
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    mirtazapine hydrate甲基叔丁基醚 为溶剂, 生成 米氮平
    参考文献:
    名称:
    Anhydrous mirtazapine crystals and process for preparing the same
    摘要:
    低吸湿性无水米氮平晶体,在相对湿度为75%、温度为25℃、大气压下存放500小时时,其吸湿度不超过0.6%。制备无水米氮平晶体的方法,包括干燥米氮平水合物晶体;米氮平水合物晶体的晶体式(I)为:其中n为1至5的整数;制备米氮平水合物晶体的方法,包括使用水溶性有机溶剂和水结晶粗米氮平。这种无水米氮平晶体可以作为抗抑郁药物等用途。
    公开号:
    US20020103372A1
点击查看最新优质反应信息

文献信息

  • Novel Pharmaceutical Forms, and Methods of Making and Using the Same
    申请人:Hickey Magali Bourghol
    公开号:US20120015993A1
    公开(公告)日:2012-01-19
    Crystalline salts, polymorphs, solvates, and hydrates of bicalutamide, 5-fluorouracil, donepezil, anastrozole, nelfinavir, mirtazapine, lansoprazole, and tamsulosin, or derivatives thereof are provided by the subject invention. Methods of making and using the same are also provided.
    本发明提供了比卡鲁胺、5-尿嘧啶多奈哌齐阿那曲唑奈非那韦米氮平兰索拉唑坦洛新的结晶盐、多晶体、溶剂化物和合物,以及它们的衍生物。同时,本发明还提供了制备和使用这些化合物的方法。
  • NOVEL PHARMACEUTICAL FORMS, AND METHODS OF MAKING AND USING THE SAME
    申请人:University of South Florida
    公开号:US20130289280A1
    公开(公告)日:2013-10-31
    Crystalline salts, polymorphs, solvates, and hydrates of bicalutamide, 5-fluorouracil, donepezil, anastrozole, nelfinavir, mirtazapine, lansoprazole, and tamsulosin, or derivatives thereof are provided by the subject invention. Methods of making and using the same are also provided.
    本发明提供了比卡鲁胺、5-尿嘧啶多奈哌齐阿那曲唑奈非那韦米氮平兰索拉唑坦洛新的晶体盐、多形体、溶剂化物和合物,或其衍生物。同时还提供了制备和使用这些物质的方法。
  • Anhydrous mirtazapine crystals and
    申请人:Sumika Fine Chemicals Co. , Ltd.
    公开号:US20030130504A1
    公开(公告)日:2003-07-10
    Low-hygroscopic anhydrous mirtazapine crystals having a hygroscopic degree of not more than 0.6% by weight when the crystals are stored in the air having a relative humidity of 75% at 25° C. under atmospheric pressure for 500 hours; a process for preparing anhydrous mirtazapine crystals having a hygroscopic degree of not more than 0.6% by weight when the crystals are stored in the air having a relative humidity of 75% at 25° C. under atmospheric pressure for 500 hours, comprising drying crystals of mirtazapine hydrate; a crystal of a mirtazapine hydrate represented by the formula (I): 1 wherein n is an integer of 1 to 5; and a process for preparing crystals of a mirtazapine hydrate, comprising crystallizing a crude mirtazapine using a water-soluble organic solvent and water. The anhydrous mirtazapine crystals can be suitably used, for instance, as an antidepressant.
    低吸湿性无米氮平晶体,当晶体在大气压下于 25°C、相对湿度为 75%的空气中贮存 500 小时时,其吸湿度不超过 0.6%(按重量计);一种制备无米氮平晶体的工艺,当晶体在大气压下于 25°C、相对湿度为 75%的空气中贮存 500 小时时,其吸湿度不超过 0.6%(重量)的无米氮平晶体的制备方法,包括干燥米氮平合物晶体;由式(I)表示的米氮平合物晶体: 1 其中 n 为 1 至 5 的整数;以及一种制备米氮平合物晶体的工艺,包括使用溶性有机溶剂和使粗米氮平结晶。无米氮平晶体可适当用作抗抑郁剂等。
  • ANHYDROUS MIRTAZAPINE CRYSTALS AND PROCESS FOR THE PRODUCTION THEREOF
    申请人:Sumitomo Chemical Company, Limited
    公开号:EP1225174B2
    公开(公告)日:2010-06-02
  • US6552189B2
    申请人:——
    公开号:US6552189B2
    公开(公告)日:2003-04-22
查看更多

同类化合物

米氮平溴化物 米氮平半水合物 米氮平-d3 米氮平 去甲米氮平-D4盐酸盐 去甲基米氮平 2-甲基-1,2,3,4,10,14B-六氢吡嗪并[2,1-a]吡啶并[2,3-C][2]苯并氮杂卓2-氧化物 10-氧代米氮平 1-氧代米氮平 1,2,3,4,10,14b-六氢-2-甲基-吡嗪并[2,1-a]吡啶并[2,3-c][2]苯并氮杂卓-8-醇 (S)-1,2,3,4,10,14b-六氢-2-甲基吡嗪并[2,1-a]吡啶并[2,3-c][2]苯并氮杂卓 (R)-1,2,3,4,10,14b-六氢-2-甲基吡嗪并(2,1-a)吡啶并(2,3-c)(2)苯并氮杂卓 dihydroaustamide (+)-austamide mirtazapine hydrate S-mirtazapine fumarate (+)-hydroaustamide (-)-N-Desmethyl-Mirtazapine (14bR)-2-(2-Phthalimidoethyl)-1,2,3,4,10,14b-hexahydropyrazino [2,1-a]pyrido[2,3-c][2]benzoazepine 1,2,3,4,10,13b-hexahydro-2-methylpiperazino<1,2-a>thieno<2,3-c><1>benzazepine 1,2,3,4,10,13b-hexahydro-2-methylpiperazino<1,2-a>thieno<3,2-c><1>benzazepine 3-methyl-1,2,3,4,4a,5,6,7-octahydropyrazino<1,2-a>-1-benzazepine 3-β-(4-pyridylethyl)-1,2,3,4,4a,5,6,7-octahydropyrazino<1,2-a>-1-benzazepine 1,2,3,4,4a,5,6,7-octahydropyrazino<1,2-a>-1-benzazepine But-2-enedioic acid--2-methyl-1,2,3,4,10,14b-hexahydropyrazino[2,1-a]pyrido[2,3-c][2]benzazepine (1/1) Mirtazapine maleate, (R)- Mirtazapine hydrobromide 8-Hydroxymirtazapine, (S)- 8-Hydroxymirtazapine, (R)- Normirtazapine, (S)- 2-methyl-1,2,3,4,10,14b-hexahydro-benzo[c]pyrazino[1,2-a]pyrido[3,4-f]azepine 5-Methyl-2,5,19-triazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(15),8,10,12,16,18-hexaene;pentahydrate 5-Methyl-2,5,19-triazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(15),8,10,12,16,18-hexaene;dihydrate N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine;5-methyl-2,5,19-triazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(15),8,10,12,16,18-hexaene 5-Methyl-2,5,19-triazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(15),8,10,12,16,18-hexaene;tetrahydrate 2-[4-(2-Methylpropyl)phenyl]propanoic acid;5-methyl-2,5,19-triazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(15),8,10,12,16,18-hexaene 5-Methyl-2,5,19-triazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(15),8,10,12,16,18-hexaene;trihydrate (7R)-17-bromo-5-methyl-2,5,19-triazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(15),8,10,12,16,18-hexaene (10aS)-1,2,3,4,6,7,8,10a-octahydropyrazino[1,2-a]azepine Mirtazapine-M (nor-HO-methoxy-) 2AC Mirtazapine-M (nor-HO-) 2AC Mirtazapine-M (nor-) AC 7,10-Dimethyl-1,2,3,4,8,9-hexahydropyrazino[1,2-a]azepine 6-Chloro-10-methyl-1,2,3,4,8,9-hexahydropyrazino[1,2-a]azepine (7R)-5-methyl-2,5,19-triazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(15),8,10,12,16,18-hexaen-6-one (10aR)-1,2,3,4,6,7,8,10a-octahydropyrazino[1,2-a]azepine Mirtazapine-M (HO-) AC ethene;(7S)-5-methyl-2,5,19-triazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(15),8,10,12,16,18-hexaene [2-chloro-3-(trifluoromethyl)phenyl]-(10-methyl-6-pyrimidin-2-yl-3,4,8,9-tetrahydro-1H-pyrazino[1,2-a]azepin-2-yl)methanone (2-chloro-4-fluorophenyl)-(10-methyl-3,4,8,9-tetrahydro-1H-pyrazino[1,2-a]azepin-2-yl)methanone